Specific classifications of “relapse” versus de novo in this population will require more thorough pathological and molecular studies, however these observations demonstrate that WT development beyond the age of 7-8 years has occurred in multiple patients with WAGR spectrum, and long-term risk may have been underrepresented in previous WAGR syndrome cohorts. The gene discussed is WT1; the disease is WAGR syndrome.